Antigen Discovery Wins $3.1M from NIAID for Work on Malaria Markers, Microfluidic Dx Device | GenomeWeb

Proteomics firm Antigen Discovery said this week that it has received two Small Business Innovation Research awards totaling roughly $3.1 million for work on protein biomarkers for malaria and an integrated microfluidic point-of-care diagnostic device.

The malaria biomarker award is a three-year, Phase II SBIR grant from the National Institute of Allergy and Infectious Disease totaling $2.5 million. The microfluidic device award is a Phase I SBIR grant, also from the NIAID, totaling $600,000.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.